Coherus Oncology (CHRS) Amortizatization of Intangibles (2015 - 2023)

Coherus Oncology has disclosed Amortizatization of Intangibles across 9 years of filings, most recently posting $595000.0 for Q4 2023.

• Amortizatization of Intangibles for Q4 2023 came in at $595000.0, down 25.62% year-over-year; the trailing twelve-month figure through Dec 2023 was $2.6 million (down 52.38% YoY), and the FY2024 annual result was $4.2 million, up 72.79% from the prior year.
• Amortizatization of Intangibles came in at $595000.0 for Q4 2023 at Coherus Oncology, up from $329000.0 in the prior quarter.
• In the past five years, Amortizatization of Intangibles ranged from a high of $3.7 million in Q1 2022 to a low of -$1.6 million in Q4 2019.
• The 5-year median for Amortizatization of Intangibles is $438000.0 (2019), against an average of $607000.0.
• Peak annual rise in Amortizatization of Intangibles reached 1143.18% in 2019, while the deepest fall reached 506.51% in 2019.
• Coherus Oncology's Amortizatization of Intangibles stood at -$1.6 million in 2019, then jumped by 163.36% to $989000.0 in 2020, then advanced by 11.93% to $1.1 million in 2021, then slipped by 27.73% to $800000.0 in 2022, then slipped by 25.62% to $595000.0 in 2023.
• The last three Amortizatization of Intangibles figures came in at $595000.0 (Q4 2023), $329000.0 (Q3 2023), and $327000.0 (Q2 2023), per Business Quant data.